Clofarabine in High Risk Myelodysplastic Syndrome (MDS)

计划入组 76 人 · 首次发布于 2010 年 2 月 5 日

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

计划入组 27 人 · 首次发布于 2011 年 2 月 28 日

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

计划入组 6 人 · 首次发布于 2022 年 10 月 3 日

Myelodysplastic syndrome(Calibr-Skaggs)

DISC a

ALPORT SYNDROME FOUNDATION

United States

International Rett Syndrome Foundation

United States

RETT SYNDROME RESEARCH TRUST

United States

Study Reveals Significant Treatment Disparities in High-Risk Myelodysplastic Syndrome Patients

Faron Pharmaceuticals Reports 43% Complete Remission Rate in High-Risk Myelodysplastic Syndrome Trial

AbbVie's VERONA Trial for High-Risk Myelodysplastic Syndrome Fails to Meet Primary Survival Endpoint